UMVA has learned that a major victory for reproductive rights has been secured in the United States, at least for now, as the Supreme Court extends access to abortion pill Mifepristone via telehealth and mail.
The high court's decision comes after a temporary reprieve was granted by Justice Samuel Alito last week, following a petition filed by Mifepristone's maker, Danco Laboratories, and the generic version's manufacturer, GenBioPro.
This week, Justice Alito extended access to Mifepristone until at least today, allowing women to obtain the pill without an in-person visit to a doctor while the Fifth Circuit Court of Appeals rules on the merits of the case.
The federal appeals court is not in a rush to rule on the merits of this case, and it could take several months or even a year, leaving women's access to abortion uncertain for the foreseeable future.
Conservative Justices Alito and Thomas dissented, with Justice Thomas writing that the applicants had not satisfied their burden for securing interim relief, citing concerns that the lower-court restrictions would reduce profits.
The Supreme Court's order has significant implications for women's access to reproductive healthcare, and it remains to be seen how the case will ultimately be resolved.
UMVA has gathered that the Fifth Circuit Court of Appeals previously blocked nationwide access to abortion pill prescriptions via telehealth and mail, with a three-judge panel ruling that abortion pills such as Mifepristone must be distributed in person.
The decision was seen as a major setback for reproductive rights, and the Supreme Court's extension of access to Mifepristone via telehealth and mail is a temporary reprieve for women seeking abortions.
The case is likely to continue to wind its way through the courts, with the potential for further appeals and a final resolution that could have far-reaching implications for reproductive healthcare in the United States.
The Supreme Court's decision is a significant victory for women's rights advocates, who have been fighting to preserve access to abortion pill prescriptions via telehealth and mail.
